Birchview Capital, LP Buys ContraFect Corp, Soleno Therapeutics Inc, Prothena Corp PLC, Sells Acceleron Pharma Inc, , Dicerna Pharmaceuticals Inc

• New Purchases: CFRX, SLNO, GOSS, AVEO, ISEE, IRTC, YTEN,
• Added Positions: PRTA, CYTK, PTGX, AZYO, BIIB, APLS, KNSA, KPTI, BLUE, ALBO,
• Reduced Positions: XLRN, ANGN, CCXI,
• Sold Out: TBIO, DRNA, HOOK,

For the details of Birchview Capital, LP's stock buys and sells, go to https://www.gurufocus.com/guru/birchview+capital%2C+lp/current-portfolio/portfolio

1. Bristol-Myers Squibb Co (BMY) - 796,106 shares, 32.05% of the total portfolio.
2. Accelerate Diagnostics Inc (AXDX) - 2,252,388 shares, 8.91% of the total portfolio. Shares added by 0.87%
3. Biodesix Inc (BDSX) - 1,104,953 shares, 6.18% of the total portfolio.
4. Quidel Corp (QDEL) - 59,684 shares, 5.73% of the total portfolio.
5. Neurocrine Biosciences Inc (NBIX) - 80,200 shares, 5.23% of the total portfolio.

Birchview Capital, LP initiated holding in ContraFect Corp. The purchase prices were between $3.19 and $4.43, with an estimated average price of $3.89. The stock is now traded at around $4.010000. The impact to a portfolio due to this purchase was 0.55%. The holding were 200,000 shares as of 2021-09-30.

Birchview Capital, LP initiated holding in Soleno Therapeutics Inc. The purchase prices were between $0.8 and $1.12, with an estimated average price of $0.93. The stock is now traded at around $0.770100. The impact to a portfolio due to this purchase was 0.55%. The holding were 876,899 shares as of 2021-09-30.

Birchview Capital, LP initiated holding in Gossamer Bio Inc. The purchase prices were between $7.25 and $13.23, with an estimated average price of $9.2. The stock is now traded at around $11.950000. The impact to a portfolio due to this purchase was 0.34%. The holding were 40,000 shares as of 2021-09-30.

Birchview Capital, LP initiated holding in AVEO Pharmaceuticals Inc. The purchase prices were between $5.12 and $6.89, with an estimated average price of $5.99. The stock is now traded at around $7.390000. The impact to a portfolio due to this purchase was 0.17%. The holding were 40,000 shares as of 2021-09-30.

Birchview Capital, LP initiated holding in IVERIC bio Inc. The purchase prices were between $7.07 and $17.5, with an estimated average price of $10.82. The stock is now traded at around $16.890000. The impact to a portfolio due to this purchase was 0.17%. The holding were 15,000 shares as of 2021-09-30.

Birchview Capital, LP initiated holding in iRhythm Technologies Inc. The purchase prices were between $41.91 and $65.79, with an estimated average price of $53.06. The stock is now traded at around $105.980000. The impact to a portfolio due to this purchase was 0.16%. The holding were 4,000 shares as of 2021-09-30.

Birchview Capital, LP added to a holding in Prothena Corp PLC by 33.06%. The purchase prices were between $48.2 and $78.89, with an estimated average price of $62.15. The stock is now traded at around $56.920000. The impact to a portfolio due to this purchase was 0.48%. The holding were 40,247 shares as of 2021-09-30.

Birchview Capital, LP added to a holding in Cytokinetics Inc by 150.00%. The purchase prices were between $18.54 and $35.74, with an estimated average price of $29.35. The stock is now traded at around $39.560000. The impact to a portfolio due to this purchase was 0.37%. The holding were 25,000 shares as of 2021-09-30.

Birchview Capital, LP added to a holding in Protagonist Therapeutics Inc by 280.00%. The purchase prices were between $12.95 and $49.69, with an estimated average price of $42.78. The stock is now traded at around $36.710000. The impact to a portfolio due to this purchase was 0.34%. The holding were 38,000 shares as of 2021-09-30.

Birchview Capital, LP added to a holding in Aziyo Biologics Inc by 66.67%. The purchase prices were between $6.75 and $9.52, with an estimated average price of $8.18. The stock is now traded at around $6.000000. The impact to a portfolio due to this purchase was 0.1%. The holding were 50,000 shares as of 2021-09-30.

Birchview Capital, LP added to a holding in Apellis Pharmaceuticals Inc by 50.00%. The purchase prices were between $31.4 and $69.84, with an estimated average price of $56.51. The stock is now traded at around $41.710000. The impact to a portfolio due to this purchase was 0.09%. The holding were 12,000 shares as of 2021-09-30.

Birchview Capital, LP added to a holding in Kiniksa Pharmaceuticals Ltd by 50.00%. The purchase prices were between $11.39 and $16.23, with an estimated average price of $13.03. The stock is now traded at around $13.092000. The impact to a portfolio due to this purchase was 0.08%. The holding were 30,000 shares as of 2021-09-30.

Birchview Capital, LP sold out a holding in . The sale prices were between $27.64 and $37.85, with an estimated average price of $34.42.

Birchview Capital, LP sold out a holding in Dicerna Pharmaceuticals Inc. The sale prices were between $19.68 and $39.99, with an estimated average price of $27.67.

Birchview Capital, LP sold out a holding in HOOKIPA Pharma Inc. The sale prices were between $5.89 and $9.35, with an estimated average price of $7.28.

Birchview Capital, LP reduced to a holding in Acceleron Pharma Inc by 42.84%. The sale prices were between $115.25 and $182.78, with an estimated average price of $130.74. The stock is now traded at around $173.740000. The impact to a portfolio due to this sale was -0.61%. Birchview Capital, LP still held 10,672 shares as of 2021-09-30.